Skip to main content

Advertisement

Table 2 Baseline patient characteristics

From: Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis

  Patients with uterine fibroids (n=17) Endometriosis
   Control (n=14) Dienogest 2 mg (n=13) LA 3.75 mg (n=16)
  baseline baseline baseline preoperation baseline preoperation
Age (years, mean ± SD 44.2 ± 6.8 34.9 ± 8.1 34.3 ± 5.7 37.5 ± 7.2
Duration of drug administration - - 21.6 ± 11.5 12.6 ± 2.8
Pelvic pain VAS (mm, mean ± SD) 23.8 ± 18.2 53.1 ± 29.9 46.2 ± 22.6a 20.6 ± 15.1b 56.3 ± 41.0ab 21.1 ± 18.0b
CA-125 (U/ml, mean ± SD) 33.1 ± 20.4 60.3 ± 34.1 60.6 ± 35.8 34.8 ± 14.9c 52.9 ± 42.8 34.9 ± 20.8
r-AFS stage (n,%)       
I: minimal 10 (58%) 0 (0%) 0 (0%) 0 (0%)
II: mild 3 (18%) 0 (0%) 0 (0%) 2 (13%)
III: moderate 4 (24%) 5 (36%) 8 (62%) 9 (56%)
IV: severe 0 (0%) 9 (64%) 5 (38%) 5 (31%)
  1. LA, leuprolide acetate; VAS, visual analogue scale; r-AFS, revised American Fertility Society.
  2. SD, standard deviation.
  3. A: p <0.01 compared to patients with uterine fibroids, b: p <0.01 compared to endometriosis-control, c: p <0.05 compared to baseline.